bioAffinity Tech

Q2 FY2026 EarningsQ2 FY2026 results missed consensus on the top line, with revenue of $1.51M failing to meet the $1.70M expectation. Despite a 216% YoY surge in CyPath Lung test volume, the GAAP net loss of $3.37M was significantly wider than the anticipated loss of $2.64M. However, Diluted EPS of -$0.64 beat the expected -$2.10, primarily driven by a massive 553% YoY increase in weighted average shares outstanding following a $3.2M public offering in June 2026, which substantially diluted the per-share loss.